Head to head
BioCryst Pharmaceuticals vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: BCRX · TAK
BCRX
BioCryst Pharmaceuticals
8.40+5.66%
1-year price shape — +21% over the period
Quant Rating D · 61/100
vs
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (70); Takeda Pharmaceutical has done best over the past year (+29%); Takeda Pharmaceutical pays the highest dividend yield.
| BCRX | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 8.40 | 18.37 |
| Change today | +5.66% | +1.49% |
| 1-year return | +20.9% | +29.2% |
| Market cap | $2.15B | $58.68B |
| 52-week range | 6.00 – 11.22 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | -6.00 | -55.67 |
| P/E percentile, own 5-yr range | 76th | 4th |
| P/B | -4.72 | 1.23 |
| Dividend yield | 0.00% | 3.26% |
| Profitability & growth | ||
| EPS (TTM) | 1.21 | -0.31 |
| Net profit (TTM) | $309.20M | $-977.54M |
| Revenue (TTM) | $940.61M | $4.62T |
| Revenue growth (YoY) | +33.6% | +10.2% |
| Gross margin | 97.8% | 65.5% |
| Operating margin | -33.3% | 10.4% |
| Net margin | -40.9% | -3.5% |
| Free cash flow (TTM) | $373.38M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 103.8% | 51.5% |
| Insider activity (12mo) | 38 buy / 9 sell | 22 buy / 28 sell |
| Short interest (% of float) | 13.6% | 0.1% |
| Analyst consensus | 71% buy / 29% hold (7) | 100% buy (1) |
| Analyst price target | $20 (+133%) | $43 (+134%) |
| StockVane view | ||
| StockVane Quant Rating | D (61) | C (70) |
| Company | ||
| Employees | 435 | 47,029 |
| Founded | 1986 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.